Merck (MRK) may be a storied pharmaceutical giant with a 134-year history, but it still has a lot of room to run. Merck is ...

With two molecules in mid-stage trials, the pharma giant is taking another swing at the difficult disease with a greater ...

Merck has characterized its cost-cutting initiative as more of a reallocation of resources to support other, higher-growth ...

Merck will reduce its workforce by approximately 6,000 employees in “some areas of our global workforce,” the New Jersey ...

A PD-L1xVEGF bispecific antibody from China’s ImmuneOnco Biopharmaceuticals has shown early promise in shrinking lung tumors, ...

Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer recently talked about. Cramer mentioned the stock and said that he liked its quarter. He remarked: “What do we make of the numbers that we ...

The remainder of 2025 will be busy for Vir Biotechnology as it strives to successfully pivot to developing cancer and infectious disease therapies.

Drug maker Merck announced Tuesday it will embark on an initiative to cut $3 billion in costs 2027, including an undisclosed amount of layoffs. The global health care company, which has U.S.

The firm is leveraging its expertise in the immuno-oncology space to expedite development of newer agents like the bispecific ...

Melbourne-based biotech VC Boson Ventures has raised $10 million of a target $30 million fund and is positioning itself as a ...

Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its best-selling ...

The 17 advisers fired last month by Robert F. Kennedy Jr. urged alternatives to ACIP be organized to limit further ...